Oncologic Drugs Advisory Committee
Committee Meeting on February 8, 2012 from 8:00 a.m. to 12:30 p.m. (Day 1 of 2)]
Agenda: The committee will discuss supplemental biologics license application 125320/28 for XGEVA (denosumab) injection, application submitted by Amgen Inc. The proposed indication (use) for this product is for the treatment of men with castrate-resistant prostate cancer at high risk of developing bone metastases, or spread of cancer to the bones.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment